

Anders RosÃ©n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/39570/publications.pdf>

Version: 2024-02-01

88
papers

4,237
citations

87888

38
h-index

114465

63
g-index

91
all docs

91
docs citations

91
times ranked

4121
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic rewiring of pathways related to odour perception in immune cells exposed to SARS-CoV-2 <i>in vivo</i> and <i>in vitro</i> . <i>Epigenetics</i> , 2022, 17, 1875-1891.	2.7	5
2	Sizing Up Extracellular DNA: Instant Chromatin Discharge From Cells When Placed in Serum-Free Conditions. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 634.	3.7	1
3	Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies. <i>Frontiers in Medicine</i> , 2020, 7, 108.	2.6	9
4	Antibodies to Human Herpesviruses in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1946.	4.8	20
5	Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E478-E487.	7.1	100
6	Immunological and Quality-of-Life Profiles in Women with Breast Cancer: Complementary versus Conventional Care. <i>Complementary Medicine Research</i> , 2018, 25, 391-397.	1.2	0
7	Infection Elicited Autoimmunity and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An Explanatory Model. <i>Frontiers in Immunology</i> , 2018, 9, 229.	4.8	97
8	Natural IgM antibodies in the immune defence against neohelminthiasis. <i>Infectious Diseases</i> , 2017, 49, 809-816.	2.8	4
9	CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. <i>Oncotarget</i> , 2017, 8, 42571-42587.	1.8	55
10	Different expression levels of glycans on leukemic cells—a novel screening method with molecularly imprinted polymers (MIP) targeting sialic acid. <i>Tumor Biology</i> , 2016, 37, 13763-13768.	1.8	41
11	Relatively high mortality risk in elderly Swedish subjects with low selenium status. <i>European Journal of Clinical Nutrition</i> , 2016, 70, 91-96.	2.9	78
12	Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation. <i>Oncotarget</i> , 2016, 7, 63456-63465.	1.8	6
13	Epigenetic silencing of tumor suppressor <i>miR-3151</i> contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. <i>Oncotarget</i> , 2015, 6, 44422-44436.	1.8	21
14	Epigenetic inactivation of <i>mir-34b/c</i> in addition to <i>mir-34a</i> and <i>DAPK1</i> in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2014, 12, 52.	4.4	35
15	Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 1722-1730.	3.5	9
16	Fe(III) distribution varies substantially within and between atherosclerotic plaques. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 885-892.	3.0	11
17	Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. <i>International Journal of Cardiology</i> , 2013, 167, 1860-1866.	1.7	127
18	Molecular characterization of neoplastic and normal <i>oesister</i> lymphoblastoid B-cell lines from chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1769-1779.	1.3	16

#	ARTICLE	IF	CITATIONS
19	A Protein Disulfide Isomerase/Thioredoxin-1 Complex Is Physically Attached to Exofacial Membrane Tumor Necrosis Factor Receptors: Overexpression in Chronic Lymphocytic Leukemia Cells. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 363-375.	5.4	23
20	450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. <i>Leukemia</i> , 2013, 27, 150-158.	7.2	95
21	Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. <i>Oncolimmunology</i> , 2012, 1, 18-27.	4.6	53
22	Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells. <i>Haematologica</i> , 2010, 95, 627-636.	3.5	7
23	Antigens in chronic lymphocytic leukemia—Implications for cell origin and leukemogenesis. <i>Seminars in Cancer Biology</i> , 2010, 20, 400-409.	9.6	68
24	A Follicular Dendritic Cell Line Promotes Somatic Hypermutations in Ramos cells <i>In Vitro</i> . <i>Scandinavian Journal of Immunology</i> , 2009, 69, 70-71.	2.7	1
25	4-Thiouridine induces dose-dependent reduction of oedema, leucocyte influx and tumour necrosis factor in lung inflammation. <i>Clinical and Experimental Immunology</i> , 2009, 155, 330-338.	2.6	6
26	Positive MRI contrast enhancement in THP-1 cells with Gd ₂ O ₃ nanoparticles. <i>Contrast Media and Molecular Imaging</i> , 2008, 3, 106-111.	0.8	60
27	A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. <i>Blood</i> , 2008, 111, 3838-3848.	1.4	236
28	Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro. <i>Haematologica</i> , 2007, 92, 1495-1504.	3.5	30
29	Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC- ζ II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. <i>Leukemia and Lymphoma</i> , 2007, 48, 2221-2232.	1.3	52
30	Redox-signaling transmitted in trans to neighboring cells by melanoma-derived TNF-containing exosomes. <i>Free Radical Biology and Medicine</i> , 2007, 43, 90-99.	2.9	91
31	What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?. <i>Hematological Oncology</i> , 2006, 24, 7-13.	1.7	13
32	Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13485-13490.	7.1	61
33	Elevated circulating levels of thioredoxin and stress in chronic heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 883-890.	7.1	86
34	Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. <i>Biochemical Pharmacology</i> , 2004, 67, 513-522.	4.4	56
35	Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. <i>Biochemical Pharmacology</i> , 2004, 67, 1721-1731.	4.4	81
36	Differentiation-associated redox-regulation in human B cell lines from stem cell/pro-B to plasma cell. <i>Immunology Letters</i> , 2004, 94, 83-89.	2.5	13

#	ARTICLE	IF	CITATIONS
37	Enzyme-Linked Immunospot Assay for Detection of Thioredoxin and Thioredoxin Reductase Secretion from Cells. <i>Methods in Enzymology</i> , 2002, 353, 22-35.	1.0	12
38	Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS). <i>Clinical and Experimental Immunology</i> , 2002, 127, 255-262.	2.6	7
39	Thioredoxin, thioredoxin reductase and tumour necrosis factor- α expression in melanoma cells : correlation to resistance against cytotoxic attack. <i>Melanoma Research</i> , 2000, 10, 331-343.	1.2	17
40	Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. <i>Blood</i> , 2000, 95, 1420-1426.	1.4	59
41	Secretion of 10-kDa and 12-kDa Thioredoxin Species from Blood Monocytes and Transformed Leukocytes. <i>Antioxidants and Redox Signaling</i> , 2000, 2, 717-726.	5.4	42
42	Thioredoxin Blood Level Increases After Severe Burn Injury. <i>Antioxidants and Redox Signaling</i> , 2000, 2, 707-716.	5.4	57
43	Monoclonal Antibodies to Human Thioredoxin Reductase. <i>Biochemical and Biophysical Research Communications</i> , 1998, 249, 86-89.	2.1	10
44	Thioredoxin Expression and Localization in Human Cell Lines: Detection of Full-Length and Truncated Species. <i>Experimental Cell Research</i> , 1997, 236, 181-192.	2.6	81
45	Human monoclonal antibodies to viral peptides. <i>Human Antibodies</i> , 1997, 8, 65-69.	1.5	1
46	Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. <i>Leukemia</i> , 1997, 11, 258-265.	7.2	158
47	Cell-cell adherence as a selection method for the generation of anti-melanoma monoclonal antibodies. <i>Journal of Immunological Methods</i> , 1997, 203, 103-109.	1.4	2
48	Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. <i>European Journal of Immunology</i> , 1996, 26, 544-551.	2.9	84
49	A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. <i>International Immunology</i> , 1995, 7, 625-633.	4.0	96
50	EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype. <i>International Journal of Cancer</i> , 1994, 58, 678-685.	5.1	20
51	Position-dependent nuclear accumulation of the retinoblastoma (RB) protein during in vitro myogenesis. <i>Journal of Cellular Physiology</i> , 1993, 155, 313-322.	4.1	10
52	CD23 and CD21 function as adhesion molecules in homotypic aggregation of human B lymphocytes. <i>European Journal of Immunology</i> , 1993, 23, 1771-1775.	2.9	64
53	Monoclonal antibody against a lactose epitope of glycosphingolipids binds to melanoma tumour cells. <i>Glycoconjugate Journal</i> , 1993, 10, 395-405.	2.7	2
54	Higher proliferative response in B-chronic lymphocytic leukemia (B-CLL) as compared to B-monoclonal lymphocytosis of undetermined significance (B-MLUS) after stimulation with <i>Staphylococcus aureus</i> and anti-CD40 monoclonal antibodies. <i>Leukemia Research</i> , 1993, 17, 933-939.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Neutralizing human monoclonal antibodies against Puumala virus, causative agent of nephropathia epidemica: a novel method using antigen-coated magnetic beads for specific B cell isolation. <i>Journal of General Virology</i> , 1993, 74, 1303-1310.	2.9	47
56	Anti-GM3-lactam monoclonal antibodies of the IgG type recognize natural GM3-ganglioside lactone but not GM3-ganglioside. <i>Glycoconjugate Journal</i> , 1992, 9, 303-306.	2.7	21
57	Cell phenotype (CD23)-dependent variation in EBV genome copy numbers within lymphoblastoid cell lines (LCL). <i>International Journal of Cancer</i> , 1992, 50, 589-592.	5.1	4
58	Human B lymphocytes possess 5-lipoxygenase activity and convert arachidonic acid to leukotriene B4. <i>Biochemical and Biophysical Research Communications</i> , 1991, 178, 302-308.	2.1	39
59	Co-localization of the retinoblastoma protein and the epstein-barr virus-encoded nuclear antigen EBNA-5. <i>Experimental Cell Research</i> , 1991, 197, 314-318.	2.6	60
60	An improved dot immunobinding assay for screening hybridoma supernatants. <i>Journal of Immunological Methods</i> , 1991, 136, 119-123.	1.4	7
61	The gene encoding CD23 leukocyte antigen (FCE2) is located on human chromosome 19. <i>Somatic Cell and Molecular Genetics</i> , 1990, 16, 283-286.	0.7	24
62	Abelson murine leukemia virus transforms preneoplastic $\frac{1}{4}$ -myc transgene-carrying cells of the B-lymphocyte lineage into plasmablastic tumors. <i>International Journal of Cancer</i> , 1990, 46, 845-852.	5.1	15
63	Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS). <i>Leukemia Research</i> , 1989, 13, 31-37.	0.8	18
64	Interleukin 4 strongly augments or inhibits DNA synthesis and differentiation of B-type chronic lymphocytic leukemia cells depending on the costimulatory activation and progression signals. <i>European Journal of Immunology</i> , 1989, 19, 913-921.	2.9	58
65	Human autoantibody secreted by immortalized lymphocyte cell line against the 68k polypeptide of the u1 small nuclear ribonucleoprotein. <i>Arthritis and Rheumatism</i> , 1988, 31, 1265-1271.	6.7	9
66	Purification and characterization of the epstein-barr virus nuclear antigen 2 using monoclonal antipeptide antibodies. <i>International Journal of Cancer</i> , 1988, 42, 721-727.	5.1	21
67	Multiple Antigen Recognition by Individual Human Monoclonal Antibodies of Rheumatic Disease Patient Origin. <i>Immunological Investigations</i> , 1988, 17, 321-335.	2.0	1
68	Human B and T lymphocytes convert leukotriene A4 into leukotriene B4. <i>Biochemical and Biophysical Research Communications</i> , 1988, 153, 203-208.	2.1	41
69	EBV-transformed lymphoblastoid cell lines down-regulate ebna in parallel with secretory differentiation. <i>International Journal of Cancer</i> , 1987, 39, 404-408.	5.1	27
70	Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines. <i>Immunology Letters</i> , 1987, 15, 249-253.	2.5	96
71	Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. <i>Journal of Virology</i> , 1987, 61, 3870-3878.	3.4	165
72	Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 1499-1503.	7.1	124

#	ARTICLE	IF	CITATIONS
73	Production of chemokinetic inhibitory factor (CIF) by normal blood and spleen B lymphocytes. <i>Leukemia Research</i> , 1986, 10, 179-186.	0.8	4
74	Routine use of counterimmunoelectrophoresis for the detection of pneumococcal antigen in sputum. <i>Medical Microbiology and Immunology</i> , 1986, 175, 241-249.	4.8	3
75	Capacity of B-lymphocytic lines of diverse tumor origin to produce and respond to B-cell growth factors: A progression model for B-cell lymphomagenesis. <i>International Journal of Cancer</i> , 1985, 35, 251-256.	5.1	60
76	UV light-induced immunoglobulin heavy-chain class switch in a human lymphoblastoid cell line. <i>Nature</i> , 1983, 306, 189-190.	27.8	32
77	Enzyme-linked immunosorbent assay for the detection of Epstein-Barr Virus-Induced Antigens and antibodies. <i>Journal of Immunological Methods</i> , 1983, 63, 171-185.	1.4	11
78	Characterization of a human ovarian teratocarcinoma-derived cell line. <i>International Journal of Cancer</i> , 1980, 25, 19-32.	5.1	158
79	AGAROSE ISOELECTRIC FOCUSING OF MONOCLONAL IgM AND IgG ANTIBODIES. , 1980, , 105-116.		10
80	Detection of virus and cellular-determined antigens in situ using [¹²⁵ I]protein A and autoradiography. <i>Journal of Immunological Methods</i> , 1979, 30, 219-229.	1.4	6
81	Agarose isoelectric focusing of native human immunoglobulin M and $\hat{\pm}$ 2-macroglobulin. <i>Journal of Immunological Methods</i> , 1979, 28, 1-11.	1.4	123
82	Target-effector interaction in the natural killer cell system: Isolation of target structures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1979, 76, 1405-1409.	7.1	111
83	Somatic cell hybrids between human lymphoma lines. IV. Establishment and characterization of a p3HR-1/daudi hybrid. <i>International Journal of Cancer</i> , 1978, 21, 707-719.	5.1	20
84	Double immunoglobulin production in cloned somatic cell hybrids between two human lymphoid cell lines. <i>Cell</i> , 1977, 11, 139-147.	28.9	14
85	Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. <i>Nature</i> , 1977, 267, 52-54.	27.8	392
86	Somatic cell hybrids between human lymphoma lines. III. Surface markers. <i>International Journal of Cancer</i> , 1977, 19, 66-76.	5.1	60
87	Structural abnormalities in chromosome 15 in cell lines with reduced expression of beta-2 microglobulin. <i>Immunogenetics</i> , 1977, 4, 567-579.	2.4	35
88	Comparison between two antibody populations in the EBV system: Anti-MA Versus neutralizing antibody activity. <i>International Journal of Cancer</i> , 1976, 17, 8-13.	5.1	23